KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Net Cash Provided by Financing Activities

Last Annual Value

159.61M

3-Year CAGR

132%

5-Year CAGR

-11%

10-Year CAGR

-6%

KT

Kalaris Therapeutics Inc Competitors Analysis of Net Cash Provided by Financing Activities

KLRS · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
159.61M
123.8%269.4%N/A 
75.21M
35.0%142.1%N/A
9.00K
-92.8%-85.7%N/A
44.57M
-2.9%87.4%N/A
-15.27K
N/AN/AN/A
-356.00K
N/AN/AN/A
120.00M
1102.6%118.7%71.2%
362.00K
-81.7%-31.9%N/A
104.96M
56.4%1.0%N/A
43.48M
-4.0%132.3%N/A
-4.74M
N/AN/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7